Biobytes

Biobytes: Turning Biobank Data into Better Aging

Biomarker discovery powered by an aging-cohort biobankFrom sarcopenia data to diagnostics and drug discovery

Explore our pipeline

Why does sarcopenia remain underexplored?

Increasing muscle mass has not yet proven how it translates into better muscle quality.

From data collection to drug discovery

STEP 1

Biobank Construction

  • Older adults, average age 71
  • Blood & muscle tissue
  • 2-hospital multicenter cohort
STEP 2

Biomarker Discovery

  • Integrated genomics & transcriptomics
  • 10 biomarkers discovered
  • Early preclinical licensing
STEP 3

Drug Discovery

  • Hit compound discovery
  • Biological pathways
  • Druggability-based tiering
  • Clinical entry

End-to-End Business Model

Pipeline

Sarcopenia(Small Molecule)

In-House

  1. Basic Research
  2. Candidate Discovery
  3. Preclinical Study
  4. Phase I
  5. Phase II
  6. Phase III

Sarcopenia(bioPROTAC)

Joint Research

  1. Basic Research
  2. Candidate Discovery
  3. Preclinical Study
  4. Phase I
  5. Phase II
  6. Phase III
View details

Partners

News

"If You Want to Walk Until You Die, Do Squats"

Herald Economy

[Notice] 35 Teams Selected for the Finals of the 14th Young Entrepreneur Competition

Unicorn Factory

Professor Jung-woo Lee Receives the Gwanghye Youth Alumni Award from Yonsei University College of Medicine Alumni Association

Daily Medi

Biobytes Wins 'Excellence Award' at K-Camp Gangwon 4th Demo Day... "Simple Diagnosis and Management of Sarcopenia"

Yakup News

Chosun University K-Bio Health Regional Center Participates in '2024 Medi-Beauty Industry Exhibition'

Daily Hankook